Form 4: Indaptus Therapeutics Director William B. Hayes Granted 12,500 Stock Options

Indaptus Therapeutics, Inc. Director William B. Hayes was granted 12,500 stock options with an exercise price of $0.33, which will vest in June 2026.

Summary

• William B. Hayes, a Director of Indaptus Therapeutics, Inc. (INDP), acquired 12,500 stock options.
• The transaction date for the option grant was June 10, 2025.
• Each stock option has an exercise price of $0.33.
• The options will vest and become exercisable on June 10, 2026.
• The expiration date for these stock options is June 10, 2035.
• Following this transaction, William B. Hayes beneficially owns 12,500 derivative securities directly.

Sentiment

Score: 6

Explanation: The grant of stock options to a director is generally viewed as a positive for aligning interests, though it's a routine compensation event and not indicative of significant operational news.

Positives

• The grant of stock options to a director aligns management's interests with those of shareholders, incentivizing long-term company performance.

Future Outlook

The stock options granted to Director William B. Hayes are set to vest on June 10, 2026, indicating a future milestone for the exercisability of these securities.

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction, specifically an equity grant, which is a common practice in the biotechnology and pharmaceutical industry to compensate and incentivize directors and executives. It does not provide broader industry trends or competitive insights.

Related Party Transactions

• The grant of stock options to a director is a transaction between the company and an insider, which is a form of related party transaction, intended for compensation and incentive.

Stakeholder Impact

• Shareholders: The grant of stock options can lead to potential future dilution if exercised, but also serves to align the director's interests with shareholder value creation.

Next Steps

• The stock options will vest and become exercisable on June 10, 2026.

Key Dates

Keywords

Indaptus Therapeutics, INDP, Stock Options, Director, Beneficial Ownership, SEC Form 4, Insider Transaction, Equity Compensation